Hennion & Walsh Asset Management, Inc. Novavax Inc Transaction History

Hennion & Walsh Asset Management, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 17, 2024	BUY	$3.76 - $6.02 $3,534 - $5,658	940 Added 7.12%	14,135 $67,000
Q4 2023 Jan 10, 2024	BUY	$4.8 - $7.67 $7,752 - $12,387	1,615 Added 13.95%	13,195 $63,000
Q3 2023 Oct 27, 2023	BUY	$6.81 - $9.74 $3,125 - $4,470	459 Added 4.13%	11,580 $83,000
Q2 2023 Aug 09, 2023	SELL	$6.67 - $9.52 $2,007 - $2,865	-301 Reduced 2.64%	11,121 $83,000
Q1 2023 Apr 20, 2023	SELL	$5.76 - $12.48 $2,079 - $4,505	-361 Reduced 3.06%	11,422 $79,000
Q4 2022 Jan 12, 2023	BUY	$8.86 - $25.04 $13,041 - $36,858	1,472 Added 14.28%	11,783 $121,000
Q3 2022 Nov 14, 2022	BUY	$18.2 - $76.12 $46,774 - $195,628	2,570 Added 33.2%	10,311 $188,000
Q2 2022 Jul 19, 2022	BUY	$36.28 - $75.29 $280,843 - $582,819	7,741 New	7,741 $398,000

290

93.4M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $680M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.